Argus analyst David Toung raised his price target on Merck to $95 and kept his Buy rating after its better than expected Q4 results, further citing the company’s approval for additional indications of Keytrude in U.S., Japan, and Europe. The analyst is also positive on Merck’s other “strong growth drivers” in Gardasil, Bridion, Lynparza, and Lenvima, as well as in animal health products.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.